Tag: Brickell Biotech

Business

Brickell Biotech Inc (NASDAQ: BBI) Announces Beginning of a Phase 1 Reading of Sofpironium Bromide Gel

Brickell Biotech Inc (NASDAQ: BBI) today announced that its improvement affiliate, Kaken Pharmaceutical Co., Ltd., newly started a Phase 1 scientific reading to evaluate the pharmacokinetics (PK) of sofpironium bromide gel in patients with critical palmoplantar hyperhidrosis (PPH) in Japan. PPH is a shared medicinal complaint of unnecessary perspiring in […]